icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
 
 
 
Bictegravir Dissociation Half-life from HIV-1
G140S/Q148H Integrase-DNA Complexes
 
 
  Reported by Jules Levin
CROI 2017 Feb 14-16 Seattle, WA
 
Kirsten White*, Anita Niedziela-Majka, Nikolai Novikov, Michael Miller, Haolun Jin, Scott Lazerwith, and Manuel Tsiang
Gilead Sciences, Foster City, CA
 
Download the PDF here
 
CROI: Randomized Trial of Bictegravir or Dolutegravir with FTC/TAF for Initial HIV Therapy - (02/16/17)
 
Webcast:http://www.croiwebcasts.org/console/player/33378?mediaType=slideVideo&
 
ASM June 2016 / CROI: Clinical Pharmacology of the Unboosted HIV Integrase Strand Transfer Inhibitor (INSTI) Bictegravir (BIC) - (02/16/17)
 
WEBCAST:http://www.croiwebcasts.org/console/player/33377?mediaType=slideVideo&
 
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.... http://aac.asm.org/content/60/12/7086.full?sid=1760f614-1eea-45c9-94aa-27af3440669b
 
Pdf attached above

0301171

0301172

0301173

0301174

0301174

0301175